Me is in trouble. Once a hot Silicon Valley startup, the genetic testing company has been in free fall since a major data ...

Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...

Per Genentech, the current price of Herceptin for a patient with “HER2 positive metastatic breast cancer” as about $50,000, a ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the ...

Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche ...

Fresenius Kabi and Formycon have won US Food and Drug Administration (FDA) approval for Otulfi (ustekinumab-aauz), a ...

Significantly more patients with moderately to severely active ulcerative colitis achieved clinical remission with the ...

On STAT's Readout LOUD podcast, Jonathan Wosen talks about Genentech shutting down its cancer immunology team, and the ...

Genentech to buy Regor's portfolio of next-generation CDK inhibitors to treat breast cancer: Cambridge, Massachusetts Tuesday, October 1, 2024, 10:00 Hrs [IST] Regor Pharmaceutica ...

Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will ...